中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.014 seconds)

    REAL-TIME CONTINUOUS GLUCOSE MONITORING BASED METHOD TO TRIGGER CARBOHYDRATES ASSUMPTION TO REVENT/MITIGATE HYPOGLYCEMIC EVENTS
    2.
    发明申请
    REAL-TIME CONTINUOUS GLUCOSE MONITORING BASED METHOD TO TRIGGER CARBOHYDRATES ASSUMPTION TO REVENT/MITIGATE HYPOGLYCEMIC EVENTS 有权

    公开(公告)号：US20220071519A1

    公开(公告)日：2022-03-10

    申请号：US17291158

    申请日：2019-11-06

    Applicant: DexCom, Inc.

    Inventor： Giovanni SPARACINO ,  Nunzio CAMERLINGO ,  Martina VETTORETTI ,  Andrea FACCHINETTI ,  Simone DEL FAVERO ,  Giacomo CAPPON

    IPC: A61B5/145 ,  A61B5/00

    Abstract: Mitigation of the risk of prolonged hypoglycemia in T1D management requires patient to assume a small dose of fast-acting carbohydrates, called hypotreatment (HT), as soon as hypoglycemia is detected. This invention consists in a method that, on the basis of the datastream generated by a continuous glucose monitoring (CGM) sensor, triggers the assumption of preventive HTs i.e., snacks that, being quickly absorbed into the circulation, avoid, or at least mitigate, a forthcoming hypoglycemic event. The method resorts to the “dynamic risk” (DR) non-linear function, which combines current glycemia with its rate-of-change provided by CGM, adapted to distinguish the severity of the about-to-happen hypoglycemia. The method has been tested in a simulated realistic scenario. Results show that the administration of an HT in advance, as triggered by the new method, brings to a strong reduction of the time that a patient would have spent in hypoglycemia assuming the HT at hypoglycemic threshold crossing.

    TIMING AND DOSING IMPROVEMENTS FOR DIABETES MANAGEMENT
    3.
    发明申请
    TIMING AND DOSING IMPROVEMENTS FOR DIABETES MANAGEMENT 有权

    公开(公告)号：US20250032710A1

    公开(公告)日：2025-01-30

    申请号：US18783288

    申请日：2024-07-24

    Applicant: Dexcom, Inc. ,  UNIVERSITÀ DEGLI STUDI DI PADOVA

    Inventor： Jacopo PAVAN ,  Giulia NOARO ,  Andrea FACCHINETTI ,  Giovanni SPARACINO ,  Simone DEL FAVERO ,  Domenico SALVAGNIN

    IPC: A61M5/172 ,  G16H20/17 ,  G16H40/67

    Abstract: In an embodiment, a system for of preventively treating hypoglycemia includes a continuous glucose monitoring (CGM) sensor system configured to generate measurements associated with a current glucose level of a patient. The system further includes one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive, from the CGM sensor system, one or more measurements associated with the current glucose level of the patient and compute a sequence of preventive hypoglycemia treatments over a future time period based on the one or more measurements and a prediction of glucose control to be produced by the sequence. The one or more processors are further configured to prompt the patient with a first preventive hypoglycemia treatment in the sequence of preventive hypoglycemia treatments.

    RETROSPECTIVE RETROFITTING METHOD TO GENERATE A CONTINUOUS GLUCOSE CONCENTRATION PROFILE BY EXPLOITING CONTINUOUS GLUCOSE MONITORING SENSOR DATA AND BLOOD GLUCOSE MEASUREMENTS
    7.
    发明公开
    RETROSPECTIVE RETROFITTING METHOD TO GENERATE A CONTINUOUS GLUCOSE CONCENTRATION PROFILE BY EXPLOITING CONTINUOUS GLUCOSE MONITORING SENSOR DATA AND BLOOD GLUCOSE MEASUREMENTS 审中-公开

    公开(公告)号：US20230210412A1

    公开(公告)日：2023-07-06

    申请号：US18182444

    申请日：2023-03-13

    Applicant: Dexcom, Inc.

    Inventor： Claudio COBELLI ,  Simone DEL FAVERO ,  Andrea FACCHINETTI ,  Giovanni SPARACINO

    IPC: A61B5/145 ,  A61B5/00 ,  A61B5/1495 ,  G16H10/40 ,  G16H50/30

    CPC classification number: A61B5/14532 ,  A61B5/1451 ,  A61B5/1495 ,  A61B5/7203 ,  A61B5/7264 ,  A61B5/7289 ,  G16H10/40 ,  G16H50/30

    Abstract: Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycaemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a “retrofitting” algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting algorithm produces an improved “retrofitted” quasi-continuous glucose concentration signal that is better (in terms of both accuracy and precision) than the CGM trace originally measured by the sensor. In clinical trials, the so-obtained retrofitted traces can be used to calculate solid outcome measures, avoiding the need of increasing the data collection burden at the patient level.

Patent Agency Ranking